Efficacy Observation of Long-term low doses of Azithromycin combined with Budesonide/Fomoterol in the treatment of stable Ⅲ to Ⅳ COPD patients
10.3969/j.issn.1006-5725.2016.17.040
- VernacularTitle:长期小剂量阿奇霉素联合布地奈德／福莫特罗治疗Ⅲ、Ⅳ级COPD稳定期患者的疗效
- Author:
Li HAN
;
Yun ZHANG
;
Tieshuan ZHANG
- Publication Type:Journal Article
- Keywords:
COPD;
Budesonide/Fomoterol;
Azithromycin
- From:
The Journal of Practical Medicine
2016;32(17):2918-2920
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the safety and efficacy of long-term low doses of Azithromycin combined with Budesonide/Fomoterol in the treatment of stable Ⅲ to Ⅳ COPD patients. Methods Collect the confirmed COPD patients of our hospital, they were randomly divided into two groups: the control group (160μg/ 4.5 μg, Bid), the joint group (160 μg/ 4.5 μg/ Bid + azithromycin 250 mg qd). Then Observe the PEF, FEV1, FEV1/FVC, mMRC, 6 MWT, AECOPD of the two groups after treatment for 3 months and 6 months. Results the index of PEF, FEV1, FEV1/FVC of joint group improved more significantly (P < 0.05) than control group after 6 months; the mMRC, 6 MWT, AECOPD, of the two groups improve the similar degree in terms of 3 months (P > 0.05), joint group improved more significantly than control group after 6 months (P < 0.05). Conclusion the therapy of Long-term low doses of azithromycin combined with Budesonide/Fomoterol can more significantly improve lung function index , as the treatment time extended , it can significantly improve clinical symptoms ,reduce the number of exacerbations than single inhaled Budesonide/Fomoterol .
